Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N04BG05
|
| gptkbp:brand |
Nouriast (Japan)
|
| gptkbp:chemicalFormula |
C20H19N5O
|
| gptkbp:drugClass |
antiparkinsonian agent
|
| gptkbp:eliminationHalfLife |
83 hours
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
istradefylline
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nourianz
|
| gptkbp:indication |
treatment of 'off' episodes in Parkinson's disease
|
| gptkbp:legalStatus |
Rx-only (US)
|
| gptkbp:manufacturer |
gptkb:Kyowa_Kirin
|
| gptkbp:marketedIn |
gptkb:Japan
gptkb:United_States |
| gptkbp:mechanismOfAction |
adenosine A2A receptor antagonist
|
| gptkbp:metabolism |
liver (CYP1A1, CYP3A4, CYP1A2)
|
| gptkbp:pregnancyCategory |
Not assigned (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
hallucination constipation insomnia dyskinesia involuntary muscle movements |
| gptkbp:usedFor |
gptkb:Parkinson's_disease
|
| gptkbp:bfsParent |
gptkb:Kyowa_Kirin
|
| gptkbp:bfsLayer |
7
|